表紙
市場調查報告書

血漿的全球市場的預測

Global Blood Plasma Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 640110
出版日期 內容資訊 英文 255 Pages
商品交期: 2-3個工作天內
價格
血漿的全球市場的預測 Global Blood Plasma Market Forecast 2020-2028
出版日期: 2020年04月13日內容資訊: 英文 255 Pages
簡介

全球血漿市場在2020年∼2028年間,預測將以6.24%的年複合成長率成長。血友病患者的增加,及老年人口的增加,運動外傷的發生率上升,治療中白蛋白製劑的使用增加等促進該市場成長。血漿,在對抗白血病和血友病之類的幾個慢性疾病中,形成要不可或缺的部分。免疫力缺乏成為癌感染疾病的主要原因,成為全球幾個地區的重要問題。由於新產品的銷售和功能強化,市場上的血漿產品的需求也提高。同時,這樣的治療方法相關的費用,及血液作為媒介的疾病感染風險,估計阻礙市場成長的要素。

本報告提供全球血漿市場調查,市場概要,各產業結構,給藥途徑、疾病、血漿來源產品、適應症、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,課題,市場佔有率,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查範圍和調查手法

  • 調查目的
  • 調查範圍
  • 調查手法
  • 前提與限制

第2章 摘要整理

  • 市場規模與預測
  • 市場概要

第3章 市場動態

  • 市場定義
  • 主要的成長要素
    • 免疫球蛋白為基礎治療方法的普及
    • 其他治療領域的白蛋白製劑的使用擴大
    • 老年人口的增加
    • Alpha-1anti胰蛋白酶缺乏症(AATD)的患病數增加
    • 血友病治療的患者群增加
    • 運動傷害的發生率的上升
  • 主要的阻礙因素
    • 治療的重組血漿產品的使用增加
    • 血漿治療的成本高
    • 輸血後的有害反應
    • 病原性污染物質展開
    • 嚴格的法規

第4章 市場分析

  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係
  • 血漿製劑相關法規
  • 臨床指南
  • 機遇矩陣
  • 業者情勢
  • 主要的投資洞察

第5章 全球血漿市場:各給藥途徑

  • 輸液
  • 凝膠
  • 噴霧
  • 生物醫療用密封膠

第6章 全球血漿市場:各疾病

  • 免疫力缺乏症
  • 低伽馬球蛋白血症
  • 血友病
  • 馮威里氏病(VWD)
  • 其他

第7章 全球血漿市場:各血漿來源產品

  • 免疫球蛋白製劑
    • 靜脈內免疫球蛋白製劑
    • 皮下免疫球蛋白製劑
    • 其他
  • 白蛋白製劑
  • 高效價免疫球蛋白製劑
  • 凝血因子
  • 其他

第8章 全球血漿市場:各適應症

  • 神經疾病
  • 免疫疾病
  • 腫瘤
  • 移植
  • 血液疾病
  • 風濕
  • 呼吸疾病
  • 其他

第9章 全球血漿市場:各終端用戶

  • 醫院、診療所
  • 研究室
  • 學術機構

第10章 全球血漿市場:各地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 俄羅斯
    • 比利時
    • 波蘭
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲、紐西蘭
    • 印度
    • 韓國
    • 泰國
    • 印尼
    • 越南
    • 其他
  • 其他地區
    • 南美
    • 中東、非洲

第11章 企業簡介

  • ADMA BIOLOGICS
  • ARTHREX
  • BIO PRODUCTS LABORATORY
  • BAXTER INTERNATIONAL
  • BIOTEST AG
  • CERUS CORPORATION (CERUS)
  • CHINA BIOLOGIC PRODUCTS
  • CSL LIMITED
  • FUSION HEALTH CARE
  • GREEN CROSS HOLDINGS CORPORATION
  • GRIFOLS
  • LFB
  • OCTAPHARMA
  • 武田藥品工業
  • KEDRION BIOPHARMA INC

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 17364

KEY FINDINGS:

The global blood plasma market is projected to register a CAGR of 6.24% during the forecast period, 2020-2028. The eminent drivers of market growth are the increasing patient pool for hemophilia treatment, the rising geriatric population, the increasing occurrence of sports injuries, and the growing usage of albumin in therapeutic areas.

MARKET INSIGHTS:

Plasma is essential for the regulation of body functions. Blood Plasma comprises of several components that are useful, like coagulation factors, immunoglobulin, protease inhibitors, and albumin. It forms an essential part of therapeutic treatment for several therapies for its potential in combating several chronic diseases like leukemia and hemophilia. Immunodeficiency is a major factor responsible for severe infections, and has become a significant concern in several parts of the world. The new product launches and enhancements are augmenting the demand for blood plasma products in the market. At the same time, the expenses involved in such therapies, and the risk of blood-borne disease transmission, are the factors estimated to impede the growth of the market. The market faces challenges like a lack of a safe blood donor base, along with the shortage of plasma fractionation facilities. The competitive nature of the market is highly intense, and the market has the presence of a limited number of players.

MARKET INSIGHTS:

The global blood plasma market is segregated geographically into Europe, North America, Asia Pacific, and the rest of the world, for further analysis. The North American region held the largest market share in 2019. Inkwood Research estimates the region to continue the trend until the end of the forecast period. The region is considered to be the epicenter for blood plasma therapy research and development activities, which is incorporated into various treatment methods in the region.

COMPETITIVE INSIGHTS:

Some of the renowned companies registering their presence in the market include, Baxter International, Biotest AG, Takeda Pharmaceutical Company, Fusion Health Care, Arthrex, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. WIDESPREAD ACCEPTANCE OF IMMUNOGLOBULIN-BASED THERAPIES
    • 3.2.2. GROWING USAGE OF ALBUMIN IN OTHER THERAPEUTIC AREAS
    • 3.2.3. GROWING GERIATRIC POPULATION
    • 3.2.4. RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
    • 3.2.5. INCREASE IN THE PATIENT POOL FOR HEMOPHILIA TREATMENT
    • 3.2.6. RISE IN OCCURRENCE OF SPORTS INJURIES
  • 3.3. KEY RESTRAINTS
    • 3.3.1. INCREASING USAGE OF RECOMBINANT PLASMA PRODUCTS IN THERAPEUTIC TREATMENTS
    • 3.3.2. HIGH COSTS OF BLOOD PLASMA TREATMENTS
    • 3.3.3. ADVERSE REACTIONS ASSOCIATED WITH POST-TRANSFUSION
    • 3.3.4. SPREAD OF PATHOGENIC CONTAMINANTS
    • 3.3.5. HIGH REGULATIONS IN THE MARKET

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. PLASMA THERAPEUTICS REGULATION
  • 4.3. CLINICAL GUIDELINES
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY MODE OF DELIVERY

  • 5.1. INFUSION SOLUTIONS
  • 5.2. GELS
  • 5.3. SPRAYS
  • 5.4. BIOMEDICAL SEALANTS

6. MARKET BY DISORDER

  • 6.1. IMMUNODEFICIENCY DISEASE
  • 6.2. HYPOGAMMAGLOBULINEMIA
  • 6.3. HEMOPHILIA
  • 6.4. VON WILLEBRAND DISEASE (VWD)
  • 6.5. OTHER DISORDERS

7. MARKET BY BLOOD PLASMA DERIVATIVES

  • 7.1. IMMUNOGLOBULIN
    • 7.1.1. INTRAVENOUS IMMUNOGLOBULIN
    • 7.1.2. SUBCUTANEOUS IMMUNOGLOBULIN
    • 7.1.3. OTHER IMMUNOGLOBULIN TYPES
  • 7.2. ALBUMIN
  • 7.3. HYPERIMMUNE
  • 7.4. COAGULATION FACTOR CONCENTRATES
  • 7.5. OTHER PLASMA FRACTIONATION PRODUCTS

8. MARKET BY THERAPEUTIC INDICATION

  • 8.1. NEUROLOGY
  • 8.2. IMMUNOLOGY
  • 8.3. ONCOLOGY
  • 8.4. TRANSPLANTATION
  • 8.5. HEMATOLOGY
  • 8.6. RHEUMATOLOGY
  • 8.7. PULMONOLOGY
  • 8.8. OTHER THERAPEUTIC INDICATION

9. MARKET BY END-USER

  • 9.1. HOSPITALS AND CLINICS
  • 9.2. RESEARCH LABORATORIES
  • 9.3. ACADEMIC INSTITUTIONS

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. THE UNITED STATES
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. THE UNITED KINGDOM
    • 10.2.2. GERMANY
    • 10.2.3. FRANCE
    • 10.2.4. ITALY
    • 10.2.5. RUSSIA
    • 10.2.6. BELGIUM
    • 10.2.7. POLAND
    • 10.2.8. REST OF EUROPE
  • 10.3. ASIA PACIFIC
    • 10.3.1. JAPAN
    • 10.3.2. CHINA
    • 10.3.3. AUSTRALIA & NEW ZEALAND
    • 10.3.4. INDIA
    • 10.3.5. SOUTH KOREA
    • 10.3.6. THAILAND
    • 10.3.7. INDONESIA
    • 10.3.8. VIETNAM
    • 10.3.9. REST OF ASIA PACIFIC
  • 10.4. REST OF WORLD
    • 10.4.1. LATIN AMERICA
    • 10.4.2. MIDDLE EAST & AFRICA

11. COMPANY PROFILES

  • 11.1. ADMA BIOLOGICS
  • 11.2. ARTHREX
  • 11.3. BIO PRODUCTS LABORATORY
  • 11.4. BAXTER INTERNATIONAL
  • 11.5. BIOTEST AG
  • 11.6. CERUS CORPORATION (CERUS)
  • 11.7. CHINA BIOLOGIC PRODUCTS
  • 11.8. CSL LIMITED
  • 11.9. FUSION HEALTH CARE
  • 11.10. GREEN CROSS HOLDINGS CORPORATION
  • 11.11. GRIFOLS
  • 11.12. LFB
  • 11.13. OCTAPHARMA
  • 11.14. TAKEDA PHARMACEUTICAL COMPANY
  • 11.15. KEDRION BIOPHARMA INC

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - BLOOD PLASMA
  • TABLE 2: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL HYPOGAMMAGLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL HYPOGAMMAGLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL HEMOPHILIA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL HEMOPHILIA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL VON WILLEBRAND DISEASE (VWD) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL VON WILLEBRAND DISEASE (VWD) MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL OTHER DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL OTHER DISORDERS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL OTHER IMMUNOGLOBULIN TYPE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL OTHER IMMUNOGLOBULIN TYPE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL ALBUMIN MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL ALBUMIN MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL HYPERIMMUNE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL HYPERIMMUNE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL OTHER PLASMA FRACTIONATION PRODUCTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL OTHER PLASMA FRACTIONATION PRODUCTS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL NEUROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: GLOBAL NEUROLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 38: GLOBAL IMMUNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: GLOBAL IMMUNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 40: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 42: GLOBAL TRANSPLANTATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 43: GLOBAL TRANSPLANTATION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 44: GLOBAL HEMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 45: GLOBAL HEMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 46: GLOBAL RHEUMATOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 47: GLOBAL RHEUMATOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 48: GLOBAL PULMONOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 49: GLOBAL PULMONOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 50: GLOBAL OTHER THERAPEUTIC INDICATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 51: GLOBAL OTHER THERAPEUTIC INDICATION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 52: GLOBAL BLOOD PLASMA MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 53: GLOBAL BLOOD PLASMA MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 54: GLOBAL HOSPITALS AND CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 55: GLOBAL HOSPITALS AND CLINICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 56: GLOBAL RESEARCH LABORATORIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 57: GLOBAL RESEARCH LABORATORIES MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 58: GLOBAL ACADEMIC INSTITUTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 59: GLOBAL ACADEMIC INSTITUTIONS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 60: GLOBAL BLOOD PLASMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 61: GLOBAL BLOOD PLASMA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 62: NORTH AMERICA BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 63: NORTH AMERICA BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 64: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, HISTORICAL YEARS 2016-2019 (IN $ MILLION)
  • TABLE 65: EUROPE BLOOD PLASMA MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 66: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 67: ASIA PACIFIC BLOOD PLASMA, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 68: REST OF BLOOD PLASMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 69: REST OF BLOOD PLASMA MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: IMMUNOGLOBULIN INFUSIONS SIDE EFFECTS
  • FIGURE 6: ROLE OF FIBRIN SEALANT IN COAGULATION CASCADE
  • FIGURE 7: GLOBAL BLOOD PLASMA MARKET, BY DISORDER, IN 2019
  • FIGURE 8: GLOBAL BLOOD PLASMA MARKET, BY IMMUNODEFICIENCY DISEASE, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL BLOOD PLASMA MARKET, BY HYPOGAMMAGLOBULINEMIA, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL BLOOD PLASMA MARKET, BY HEMOPHILIA, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL BLOOD PLASMA MARKET, BY VON WILLEBRAND DISEASE (VWD), 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL BLOOD PLASMA MARKET, BY OTHER DISORDERS, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL BLOOD PLASMA MARKET, BY BLOOD DERIVATIVES, IN 2019
  • FIGURE 14: GLOBAL BLOOD PLASMA MARKET, BY IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2020-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER IMMUNOGLOBULIN TYPES, 2020-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL BLOOD PLASMA MARKET, BY ALBUMIN, 2020-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL BLOOD PLASMA MARKET, BY HYPERIMMUNE, 2020-2028 (IN $ MILLION)
  • FIGURE 20: HYPERIMMUNES ISOLATION PROCESS
  • FIGURE 21: GLOBAL BLOOD PLASMA MARKET, BY COAGULATION FACTOR CONCENTRATES, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL BLOOD PLASMA MARKET, BY OTHER PLASMA FRACTIONATION PRODUCTS, 2020-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL BLOOD PLASMA MARKET, BY THERAPEUTIC INDICATION, IN 2019
  • FIGURE 24: GLOBAL BLOOD PLASMA MARKET, BY NEUROLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL BLOOD PLASMA MARKET, BY IMMUNOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL BLOOD PLASMA MARKET, BY ONCOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL BLOOD PLASMA MARKET, BY TRANSPLANTATION, 2020-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL BLOOD PLASMA MARKET, BY HEMATOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL BLOOD PLASMA MARKET, BY RHEUMATOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 30: LUPUS INFECTION SYMPTOMS
  • FIGURE 31: GLOBAL BLOOD PLASMA MARKET, BY PULMONOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL BLOOD PLASMA MARKET, BY OTHER THERAPEUTIC INDICATION, 2020-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL BLOOD PLASMA MARKET, BY END-USER, IN 2019
  • FIGURE 34: GLOBAL BLOOD PLASMA MARKET, BY HOSPITALS AND CLINICS, 2020-2028 (IN $ MILLION)
  • FIGURE 35: GLOBAL BLOOD PLASMA MARKET, BY RESEARCH LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL BLOOD PLASMA MARKET, BY ACADEMIC INSTITUTIONS, 2020-2028 (IN $ MILLION)
  • FIGURE 37: NORTH AMERICA BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 38: THE UNITED STATES BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: CANADA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: EUROPE BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 41: THE UNITED KINGDOM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 42: GERMANY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 43: FRANCE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 44: ITALY BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: RUSSIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: BELGIUM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 47: POLAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 48: REST OF EUROPE BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 49: ASIA PACIFIC BLOOD PLASMA MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 50: JAPAN BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 51: CHINA BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 52: AUSTRALIA & NEW ZEALAND BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 53: INDIA BLOOD PLASMA, 2020-2028 (IN $ MILLION)
  • FIGURE 54: SOUTH KOREA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 55: THAILAND BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 56: INDONESIA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 57: VIETNAM BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 58: REST OF ASIA PACIFIC BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 59: REST OF WORLD BLOOD PLASMA MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 60: LATIN AMERICA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 61: MIDDLE EAST & AFRICA BLOOD PLASMA MARKET, 2020-2028 (IN $ MILLION)